Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of TAK-931 monotherapy in advanced solid tumors
jRCT2080223638Phase 2Completed
- Sponsor
- Takeda
- Start
- Sep 2017
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of simurosertib in pancreatic adenocarcinoma (PDAC), colorectal adenocarcinoma (mCRC), Esophageal Squamous Cell Carcinoma (ESCC) and 2 more, sponsored by Takeda. Primary endpoint: Safety and tolerability of TAK-931. Started Sep 2017; status: completed.
02
Drugs
simurosertib
03
Conditions
pancreatic adenocarcinoma (PDAC)colorectal adenocarcinoma (mCRC)Esophageal Squamous Cell Carcinoma (ESCC)non-small cell lung cancer (NSCLC)Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2080223638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223638.